SG Americas Securities LLC Sells 554 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

SG Americas Securities LLC reduced its position in Charles River Laboratories International, Inc. (NYSE:CRL) by 25.2% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 1,644 shares of the medical research company’s stock after selling 554 shares during the period. SG Americas Securities LLC’s holdings in Charles River Laboratories International were worth $303,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in the business. Mitchell & Pahl Private Wealth LLC lifted its stake in shares of Charles River Laboratories International by 8.8% during the 4th quarter. Mitchell & Pahl Private Wealth LLC now owns 3,603 shares of the medical research company’s stock valued at $665,000 after buying an additional 292 shares in the last quarter. Kera Capital Partners Inc. purchased a new stake in shares of Charles River Laboratories International during the fourth quarter worth $246,000. Pinnacle Bancorp Inc. boosted its holdings in shares of Charles River Laboratories International by 52.0% in the fourth quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company’s stock worth $35,000 after acquiring an additional 65 shares during the period. Fiduciary Financial Group LLC raised its stake in shares of Charles River Laboratories International by 3.9% during the 4th quarter. Fiduciary Financial Group LLC now owns 1,665 shares of the medical research company’s stock valued at $310,000 after purchasing an additional 63 shares during the period. Finally, Czech National Bank lifted its holdings in Charles River Laboratories International by 5.4% during the 4th quarter. Czech National Bank now owns 11,088 shares of the medical research company’s stock worth $2,047,000 after purchasing an additional 571 shares in the last quarter. 98.91% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Charles River Laboratories International

In related news, Director Richard F. Wallman sold 6,621 shares of Charles River Laboratories International stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $216.12, for a total value of $1,430,930.52. Following the transaction, the director now directly owns 12,386 shares of the company’s stock, valued at $2,676,862.32. The trade was a 34.83 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 1.30% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the company. Bank of America decreased their price target on Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating on the stock in a research report on Friday, December 13th. StockNews.com cut shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a research note on Thursday, November 7th. The Goldman Sachs Group reduced their price target on shares of Charles River Laboratories International from $220.00 to $190.00 and set a “buy” rating for the company in a research report on Thursday, January 23rd. William Blair downgraded Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a research report on Wednesday, January 22nd. Finally, TD Cowen boosted their target price on Charles River Laboratories International from $203.00 to $227.00 and gave the stock a “hold” rating in a research report on Monday, November 11th. Three analysts have rated the stock with a sell rating, thirteen have assigned a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $202.08.

Charles River Laboratories International Price Performance

Shares of NYSE:CRL opened at $162.95 on Wednesday. The company has a quick ratio of 1.14, a current ratio of 1.48 and a debt-to-equity ratio of 0.61. The stock has a market cap of $8.33 billion, a PE ratio of 20.39, a PEG ratio of 6.25 and a beta of 1.37. The company’s fifty day moving average is $182.67 and its 200 day moving average is $194.47. Charles River Laboratories International, Inc. has a 52 week low of $159.65 and a 52 week high of $275.00.

Charles River Laboratories International (NYSE:CRL) last released its earnings results on Wednesday, November 6th. The medical research company reported $2.59 earnings per share for the quarter, beating analysts’ consensus estimates of $2.43 by $0.16. The company had revenue of $1.01 billion during the quarter, compared to analyst estimates of $975.99 million. Charles River Laboratories International had a return on equity of 14.29% and a net margin of 10.44%. Charles River Laboratories International’s revenue for the quarter was down 1.6% on a year-over-year basis. During the same quarter in the previous year, the company posted $2.72 EPS. Research analysts anticipate that Charles River Laboratories International, Inc. will post 10.17 earnings per share for the current year.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).